Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.56 (
caspase-3
)
35,750
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sorbus commixta
Hedl. (Rosaceae family) has a long history as a medicinal plant in East Asian countries. In this study, we evaluated the effect of
S. commixta
fruit extracts prepared with different ethanol concentrations on anti-melanoma activity, and the extraction yield of phenolic compounds and flavonoids. Using the partitioned fractions from the EtOH extract, we found that the butanol fraction (BF) possessed strong cytotoxic activity against SK-
MEL
-2 cells (human melanoma cells) but not against HDFa cells (human dermal fibroblast adult cells). Additionally, BF-induced cell death was mediated by the inhibition of the mitogen-activated protein kinase/extracellular regulated kinase (MEK/ERK) signaling pathway, coupled with the upregulation of
caspase-3
activity in SK-
MEL
-2 cells. Furthermore, HPLC analysis of polyphenolic compounds suggested that
S. commixta
fruits contained several active compounds including chlorogenic acid, rutin, protocatechuic acid, and hydroxybenzoic acid, all of which are known to possess anti-cancer activities. Although this study has been carried out by cell-based approach, these results suggest that
S. commixta
fruits contain promising anti-melanoma compounds.
...
PMID:Anti-Melanoma Activities and Phytochemical Compositions of
Sorbus commixta
Fruit Extracts. 3282 98
Three new series of paracyclophanyl-dihydronaphtho[2,3-
d
]thiazoles and paracyclophanyl-thiazolium bromides were designed, synthesized, and characterized by their spectroscopic data, along with X-ray analysis. One-dose assay results of anticancer activity indicated that
3a
-
e
had the highest ability to inhibit the proliferation of different cancer cell lines. Moreover, the hybrids
3c
-
e
were selected for five-dose analyses to demonstrate a broad spectrum of antitumor activity without apparent selectivity. Interestingly,
series I
compounds (
Z
)-
N
-substituted-4,9-dihydronaphtho[2,3-
d
]thiazol-3(2
H
)-yl)-4'-[2.2]paracyclophanylamide) that are carrying 1,4-dihydronaphthoquinone were more active as antiproliferative agents than their naphthalene-containing congeners (series II: substituted 2-(4'-[2.2]paracyclophanyl)hydrazinyl)-4-(naphth-2-yl)-thiazol-3-ium bromide hybrids) and (series III: 3-(4'-[2.2]paracyclophanyl)amido-2-(cyclopropylamino)-4-(naphth-2-yl)thiazol-3-ium bromide) toward the SK-
MEL
-5 melanoma cell line. Further antiproliferation investigations of
3c
and
3e
on the healthy, normal unaffected SK-
MEL
-5 cell line indicated their relative safety. Compound
3c
showed an inhibition of eight isoforms of cyclin-dependent kinases (CDK); however, it exhibited the lowest IC
50
of 54.8 nM on CDK1 in comparison to Dinaciclib as a reference. Additionally, compound
3c
revealed a remarkable downregulation of phospho-Tyr15 with a level (7.45 pg/mL) close to the reference.
3c
mainly showed cell cycle arrest in the pre-G1 and G2/M phases upon analysis of the SK-
MEL
-5 cell line. The sequential
caspase-3
assay for
3c
indicated a remarkable overexpression level. Finally, a molecular docking study was adopted to elucidate the binding mode and interactions of the target compounds with CDK1.
...
PMID:Design, Synthesis, and Molecular Docking of Paracyclophanyl-Thiazole Hybrids as Novel CDK1 Inhibitors and Apoptosis Inducing Anti-Melanoma Agents. 3326 Sep 54
<< Previous
1
2
3
4
5